600 MHz NMR Spectrometer for Solution-state NMR

描述（由申请人提供）：要求提供600 MHz NMR光谱仪的资金，以满足NIH用户组的溶液状态NMR需求，该用户组由加州大学伯克利分校化学系的七名教师组成，他们总共由20个主要NIH赠款资助。新仪器将取代过时的500 MHz光谱仪（即布鲁克DRX-500，由22年的牛津仪器磁铁和10年的电子控制台组成）。NIH用户组的NMR需求需要600 MHz磁体提供的灵敏度和分辨率。新仪器必须适应NIH用户组广泛的NMR应用，需要至少两种不同的探针，即用于依赖于高灵敏度1H检测的实验的三重共振宽带反向探针和用于高灵敏度直接检测13 C和1H以外的各种核的宽带观察探针。600 MHz NMR将极大地加速由10名教师（7名主要用户和3名次要用户）组成的研究小组进行的科学研究，并获得24项不同的NIH赠款。这项研究对人类健康具有明显的重大影响，包括发现和表征新的治疗靶点，设计和合成小分子配体作为开发治疗严重人类疾病药物的起始化合物，开发基于纳米的药物和疫苗递送载体，以及开发用于疾病诊断和预后的新的灵敏化学传感方法，例如第二代MRI试剂。

DESCRIPTION (provided by applicant): Funding is requested for a 600-MHz NMR spectrometer to accommodate the solution state NMR needs of the NIH User Group comprised of seven established faculty in the UC Berkeley Department of Chemistry who in aggregate are funded by 20 major NIH grants. The new instrument will replace an outdated 500-MHz spectrometer (namely, a Bruker DRX-500, comprised of a 22-year old Oxford Instruments magnet and 10-year old electronics console). The NMR needs of the NIH User Group require the sensitivity and resolution provided by a 600-MHz magnet. The new instrument must accommodate the NIH User Group's broad range of NMR applications, calling for at least two different probes, namely, a triple-resonance broadband inverse probe for experiments that depend on high-sensitivity 1H detection and a broadband-observe probe for high-sensitivity direct detection of 13C and a variety of nuclei other than 1H. The 600-MHz NMR will greatly accelerate the science carried out by the research groups of ten faculty (seven major and three minor users) with funding from 24 distinct NIH grants. This research has clear, significant impact on human health, including the discovery and characterization of new therapeutic targets, the design and synthesis of small molecule ligands as the starting compounds for the development of drugs to treat serious human diseases, the development of nano-based delivery vehicles for drugs and vaccines, and the development of new sensitive chemical sensing methods for disease diagnosis and prognosis such as second generation MRI agents.